Hepatocellular carcinoma (HCC) is a frequent cancer with limited treatment options and poor prognosis. Tumorigenesis has been linked with macrophage-mediated chronic inflammation and diverse signalling pathways, including the epidermal growth factor receptor (EGFR) pathway. The precise role of EGFR in HCC is unknown, and EGFR inhibitors have shown disappointing clinical results. Here we discover that EGFR is expressed in liver macrophages in both human HCC and in a mouse HCC model. Mice lacking EGFR in macrophages show impaired hepatocarcinogenesis, whereas mice lacking EGFR in hepatocytes unexpectedly develop more HCC owing to increased hepatocyte damage and compensatory proliferation. Mechanistically, following interleukin-1 stimulation, EGFR is required in liver macrophages to transcriptionally induce interleukin-6, which triggers hepatocyte proliferation and HCC. Importantly, the presence of EGFR-positive liver macrophages in HCC patients is associated with poor survival. This study demonstrates a tumour-promoting mechanism for EGFR in non-tumour cells, which could lead to more effective precision medicine strategies.
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related mortality worldwide 1 . Main risk factors for HCC include hepatitis B or C infection, alcoholic liver injury, nonalcoholic steatohepatitis, environmental carcinogens and hereditary metabolic diseases 2 , which can lead to chronic hepatitis or cirrhosis, conditions regarded as preneoplastic stages 3 . Current treatment options are limited, which may be due to the lack of biomarkers for patient stratification, as there is limited use of biopsies for HCC diagnosis, which is largely based on radiological criteria 4 . Therefore, a better understanding of the mechanisms driving HCC development is needed.
Persistent infections, activation of liver-resident macrophages (Kupffer cells) and recruitment of inflammatory cells can lead to chronic inflammation [5] [6] [7] [8] accompanied by many factors favouring HCC development 9 . The molecular link between inflammation and HCC is not completely understood. Cytokines such as interleukin-1 and 6 (IL-1 and IL-6, respectively) play a central role in liver carcinogenesis. IL-6 is produced by Kupffer cells following stimulation with IL-1, which is released by dying hepatocytes 10, 11 . IL-6 is responsible for compensatory proliferation of damaged hepatocytes, leading eventually to HCC development 12 . Many signalling pathways involved in HCC development, such as MYD88, JNK1/2, p38α and IKKβ, can regulate hepatic IL-6 production, although the precise mechanism is unclear. Moreover, JNK1, p38 and IKKβ have been shown to be involved in human HCC (refs 13-15) , and their deletion in parenchymal versus non-parenchymal cells can differentially affect hepatocarcinogenesis in mice 7, 10, 12, 13, [16] [17] [18] [19] .
Epidermal growth factor receptor (EGFR) overexpression, which occurs in 40-70% of human HCCs, has been linked with tumorigenesis 20 . Elevated expression of the EGFR ligand TGFα has been reported in preneoplastic lesions, suggesting a role in early HCC (ref. 21) . EGFR antagonists were effective in human HCC cells and in a rat HCC model 22, 23 . In clinical trials with unselected patients, erlotinib has shown moderate effects in phase II, whereas gefitinib and cetuximab have provided only disappointing results in advanced stage HCC patients 2 . Moreover, the SEARCH trial, the only phase III study carried out, was unable to show survival improvement with erlotinib in advanced stage HCC (ref. 24) . Therefore, a better understanding of the mechanisms whereby EGFR signalling influences HCC progression is needed. Genetically modified mouse models represent an invaluable tool to dissect the interplay between tumour and stromal cells during HCC development and to identify important signalling pathways in the respective cell types. Here, we employed mice lacking EGFR in different cell types of the liver to dissect the role of different cellular players and signalling pathways in HCC development.
RESULTS

HCC formation in mice lacking EGFR in all liver cells
To investigate the function of EGFR during HCC formation, we employed polyinosinic-polycytidylic acid (pIpC)-inducible Mx-Cre transgenic mice (EGFR f/f ;Mx-Cre=EGFR ∆Mx ), which delete the EGFR from parenchymal and non-parenchymal liver cells as well as several other organs 25 . We used the diethylnitrosamine/phenobarbital (DEN/PB) protocol 26 to induce HCC ( Supplementary Fig. 1a ), which occurs similarly to the human disease. DEN-damaged hepatocytes undergo apoptosis and are replaced through compensatory proliferation of surviving hepatocytes, which can give rise to HCC if mutated by DEN (ref. 27) . Complete EGFR deletion from EGFR ∆Mx tumour and non-tumour tissue was confirmed by immunohistochemistry and Southern and western blot analysis (Fig. 1a,b and Supplementary Fig. 1b ). By 46 weeks, EGFR f/f livers developed tumours, whereas EGFR ∆Mx livers showed a marked decrease in tumour mass, area and number (Fig. 1c,d ). Analysis of EGFR ∆Mx mice revealed a significant decrease in proliferation and an increase in apoptosis in HCC ( Fig. 1e ), but not in adjacent non-tumour tissue ( Supplementary Fig. 1c ). These results suggest that EGFR in liver cells promotes HCC formation by protecting them from DEN-induced apoptosis.
HCC formation in mice lacking EGFR in parenchymal cells
Given the complexity of HCC and the involvement of different cell types, we induced HCC in mice lacking EGFR specifically in hepatocytes and bile duct cells (EGFR f/f ;Alfp-Cre=EGFR ∆hep ; ref. 25 ; Supplementary Fig. 1a ). Absence of EGFR from parenchymal cells was confirmed by immunohistochemistry and western blot analysis in tumour and non-tumour tissue (Fig. 1f,g) . In EGFR ∆hep tumours, EGFR was detectable in non-parenchymal cells (Fig. 1f) , where Alfp-Cre is not expressed, which explains the unrecombined flox allele in the Southern blot ( Supplementary Fig. 1b ). In direct contrast to EGFR ∆Mx mice, EGFR ∆hep mice developed significantly larger HCCs than littermate control mice ( Fig. 1h,i) . This result was unexpected, as EGFR is believed to be tumour-promoting. Proliferation in EGFR ∆hep tumours was increased, in contrast to what was observed in EGFR ∆Mx tumours (Fig. 1j ). However, similar to EGFR ∆Mx , EGFR ∆hep tumours showed increased apoptosis ( Fig. 1j ), suggesting that EGFR protects hepatocytes against DEN-induced apoptosis.
To investigate this in more detail, we monitored liver damage at different times after DEN injection. Serum aspartate transaminase and alanine transaminase levels, markers of acute liver toxicity, were significantly increased in EGFR ∆Mx and EGFR ∆hep livers when compared with controls ( Supplementary Fig. 1e ,f). Moreover, after DEN injection, damaged areas were also significantly increased ( Fig. 1k and Supplementary Fig. 1d ) and higher levels of cleaved caspase 3 were detected in zone III of the liver lobule, where DEN is mainly metabolized 28 ( Fig. 1l and Supplementary Fig. 1g ). To investigate if this hepatocyte damage was cell autonomous, we stimulated isolated hepatocytes with DEN, and carried out immunofluorescent staining for the necrotic marker high mobility group box 1 (HMGB1; ref. 29) , which revealed a strong necrotic response specifically in EGFR-deficient hepatocytes ( Supplementary  Fig. 1h ). They were also more sensitive to apoptosis after TNFαcycloheximide treatment ( Supplementary Fig. 1i ). Thus, apoptosis and necrosis are responsible for increased DEN-induced liver damage in EGFR ∆Mx and EGFR ∆hep mice, revealing that EGFR fulfils an important death-protecting function in hepatocytes.
During toxic hepatic injury, pro-inflammatory cytokines such as IL-1 and IL-6 activate an inflammatory repair process 11 . Quantitative PCR with reverse transcription (qRT-PCR) analysis of hepatocytes isolated after DEN injection revealed a significant increase in IL-1β expression in EGFR ∆Mx and EGFR ∆hep mice, whereas IL-1α expression was low and unchanged ( Fig. 1m ). In contrast, when IL-1α/β levels were measured in total livers after DEN treatment, we observed that IL-1α was higher than IL-1β expression ( Fig. 1n ), which confirms previous results 11 . Together, these results suggest that IL-1α is mainly released by non-parenchymal cells, possibly Kupffer cells/liver macrophages, and not by damaged hepatocytes. Increased IL-1β expression was also detected in EGFR ∆Mx and EGFR ∆hep tumours ( Fig. 1o) . Moreover, increased IL-1β release was observed when EGFR-deficient hepatocytes were treated in vitro with DEN or TNFα ( Supplementary Fig. 2a,b ). Thus, hepatoprotection through EGFR signalling prevents continuous hepatocyte death and IL-1β release in HCC.
In both EGFR ∆Mx and EGFR ∆hep mice, EGFR protects cells from DEN-induced damage, but it still plays opposing roles in promoting HCC formation, illustrating its complex role in tumorigenesis. To exclude the possibility that timing of EGFR deletion (late gestation in EGFR ∆hep mice versus seven-week-old EGFR ∆Mx mice) is responsible for the differences in HCC development between the two models, we deleted EGFR shortly after birth in EGFR f/f ;Mx-Cre mice (EGFR ∆Mx * ; Supplementary Figs 1a and 2c ). Similarly to EGFR ∆Mx mice, EGFR ∆Mx * mice also developed significantly fewer and smaller tumours than their littermate controls ( Supplementary Fig. 2d,e ), suggesting that the cell types from which EGFR is deleted account for the differences in HCC development between EGFR ∆Mx and EGFR ∆hep mice.
EGFR expression in Kupffer cells/liver macrophages promotes HCC development
We hypothesized that the difference in HCC formation between EGFR ∆hep and EGFR ∆Mx mice was caused by EGFR function in nonparenchymal cells. We therefore carried out immunohistochemistry for non-parenchymal cell markers and observed a fourfold increase of F4/80-positive cells, which could be Kupffer cells or infiltrating macrophages in EGFR ∆hep tumours ( Fig. 2a,b ). There was significant upregulation of serum CCL2, a chemokine known to attract F4/80-positive cells, in EGFR ∆hep , but not in EGFR ∆Mx tumours ( Fig. 2a,b ). To test if EGFR-expressing liver macrophages could contribute to increased HCC formation in EGFR ∆hep mice, we Supplementary Table 1 and uncropped blots in Supplementary Fig. 6 . Student's t-test for independent samples and unequal variances was used to assess statistical significance ( * P < 0.05, * * P < 0.01, * * * P < 0.001).
Original data are provided in Supplementary Table 1 and uncropped gel in Supplementary Fig. 6 .
employed LysM-Cre transgenic mice to generate EGFR ∆hep/∆mac (EGFR f/f ;Alfp-Cre;LysM-Cre) mice, which lack EGFR in both hepatocytes and Kupffer cells/macrophages ( Fig. 2c ). Similarly to EGFR ∆Mx , EGFR ∆hep/∆mac mice showed significantly smaller tumours when compared with control and EGFR ∆hep mice ( Fig. 2d ,e). Thus, increased HCC formation in EGFR ∆hep mice is caused by increased numbers of EGFR-expressing Kupffer cells/infiltrating macrophages. Finally, to test whether EGFR-expressing macrophages are responsible for HCC formation, we induced HCC in mice lacking EGFR only in macrophages (EGFR f/f ;LysM-Cre=EGFR ∆mac ). Similarly to EGFR ∆Mx and EGFR ∆hep/∆mac mice, EGFR ∆mac mice showed significantly smaller tumours when compared to the respective controls ( Fig. 2d,e ). Thus, our results reveal an unexpected tumour-promoting role for EGFR in Kupffer cells/liver macrophages during HCC formation.
EGFR expression is induced in activated Kupffer cells/liver macrophages under pathological conditions
Immunofluorescent staining revealed that EGFR was expressed in Kupffer cells/macrophages isolated from EGFR f/f livers and stimulated with IL-1β in vitro (Fig. 3a ), a finding that could be confirmed by western blot (Fig. 3c ). As expected, no EGFR expression was detected in Kupffer cells isolated from EGFR ∆mac or EGFR ∆Mx mice (Fig. 3b ,c). EGFR levels in EGFR ∆hep Kupffer cells were similar to those in control cells, whereas EGFR was present in hepatocytes isolated from EGFR ∆mac but not from EGFR ∆hep or EGFR ∆Mx mice (Fig. 3c ).
Healthy and untreated EGFR f/f livers contained very few EGFRpositive Kupffer cells ( Fig. 3d ,f). However, 5 days after DEN injection, prominent EGFR expression was detected in F4/80-positive cells ( Fig. 3e ,f). Interestingly, increased levels of EGFR were also present in hepatocytes following DEN treatment ( Fig. 3g ). We next investigated whether EGFR was induced in Kupffer cells/liver macrophages of HCCs. Immunohistochemistry on serial sections of EGFR f/f and EGFR ∆hep/∆mac tumours revealed co-expression of EGFR and F4/80 in tumour and adjacent tissue of EGFR f/f (Fig. 3h,j) , but not of EGFR ∆hep/∆mac mice ( Fig. 3i,k) . These findings suggest that EGFR expression is induced in activated Kupffer cells/liver macrophages under pathological conditions.
The presence of EGFR-expressing Kupffer cells/liver macrophages in human HCC correlates with poor prognosis
We next investigated if EGFR expression in Kupffer cells/liver macrophages is relevant for human HCC, and analysed EGFR expression in 129 surgically resected HCC samples, predominantly hepatitis B (HBV)-positive from China, in the respective adjacent noncancerous tissue and in 15 'normal' livers (Table 1a,b). As chronic HBV is a less common cause of HCC in Europe, we furthermore investigated EGFR expression in 108 European HCC patients, who underwent liver transplantation for HCC (Table 1a ). This cohort had predominantly alcohol-, non-alcoholic steatohepatitis-and hepatitis C (HCV)-induced liver cirrhosis (Table 1b) Original data are provided in Supplementary Table 1 and uncropped blots in Supplementary Fig. 6 .
both cohorts was examined and blindly scored by two independent pathologists using a previously published scale 30 .
In the Chinese cohort, about 73% of normal livers were negative (0) for EGFR expression in hepatocytes, and there was no difference in EGFR expression levels (+, ++, +++) among tumour cells and hepatocytes of the adjacent non-cancerous tissue and normal livers (Table 1a and Supplementary Fig. 3a ). High expression of EGFR (++, +++) was more prevalent in HCC when compared with normal tissue (Table 1a and Supplementary Fig. 3a ), which confirms previous reports 20 . Similar results were observed for EGFR expression in hepatocytes and tumour cells of the European cohort (Table 1a) . For both cohorts, EGFR expression in tumour cells did not show significant prognostic value for patients' overall (OS) or disease-free survival (DFS) after surgery ( Supplementary Fig. 3b -e and Table 1a ), and no relationship between EGFR expression in hepatocytes and clinicopathological characteristics was found.
To analyse EGFR expression in liver macrophages we stained adjacent tissue sections for EGFR and the macrophage marker CD68. In 'normal' liver tissue, all CD68-positive cells did not express EGFR (Table 1a ). In contrast, 45% of Chinese and 34% of European samples harboured EGFR-expressing CD68-positive cells in the tumours ranging from + to +++ (Fig. 4a,b and Supplementary Fig. 3f and Table 1a ). EGFR-expressing macrophages were also present within the non-cancerous tissue adjacent to the carcinoma: 12% for the Chinese and 27% for the European cohort. The higher number of EGFR-positive macrophages in adjacent tissue of the European samples might reflect the more advanced cirrhosis in these livers. The specificity of EGFR and CD68 co-expression was confirmed by costaining in fresh frozen human HCC samples ( Supplementary Fig. 3g ). EGFR-expressing macrophages in HCCs were associated with poor clinical outcome of Chinese patients after surgical tumour resection and of European patients after liver transplantation, mirrored by significantly reduced OS and DFS ( Fig. 4c-f ). α-fetoprotein, an HCC tumour marker, was significantly higher in HCC patients with EGFRpositive macrophages (Table 1b ). In the European cohort, EGFRpositive macrophages were associated with more aggressive tumours and patients suffering from HCC recurrence after liver transplantation had EGFR-positive macrophages in their tumours (Table 1b) . To analyse whether total numbers of CD68-positive cells-regardless of EGFR expression-had an impact on HCC prognosis, we grouped patient samples into low and high macrophage counts, considering the median of the respective patient cohorts as the cut-off. For the European cohort, the number of Kupffer cells/liver macrophages alone was not predictive for OS and DFS ( Fig. 4i,j) . However, total numbers of macrophages negatively correlated with OS and DFS of Chinese patients (Fig. 4g,h) . Collectively, these data demonstrate that it is not the overall number of liver macrophages, but the number of EGFRpositive liver macrophages present in HCC, which is predictive for OS and DFS.
EGFR-deficient Kupffer cells fail to produce IL-6
We next analysed the mechanism whereby EGFR signalling in macrophages promotes tumorigenesis. IL-6 is produced at high levels by Kupffer cells in response to IL-1 derived from damaged hepatocytes, and European cohorts (i,j: 108 patients; n = 50 with low and n = 58 with high counts). For the respective patient cohorts, low was classified as values below or at the 50th percentile and high was classified as values above the 50th percentile. Scoring system: 0, negative staining (0-10% positive); 1, weak signal (10-20% positive); 2, intermediate signal (20-50% positive); 3, strong signal (>50% positive) as previously described 30 . A log-rank test was used to assess statistical significance.
and stimulates compensatory hepatocyte proliferation through IL-6R activation 10, 11 . We found IL-6 serum levels to be strongly induced after DEN injection in EGFR f/f and EGFR ∆hep mice, but not in EGFR ∆Mx or EGFR ∆hep/∆mac mice, which are deficient for EGFR in macrophages (Fig. 5a ). Importantly, we also found significantly higher IL-6 levels in the plasma of Chinese HCC patients showing EGFRpositive Kupffer cells in their tumours (Fig. 5b ). This occurred in association with HBV infection (Fig. 5c ), suggesting that infections and inflammatory conditions lead to upregulation of EGFR in Kupffer cells with consequent increased IL-6 production. For the European cohort, patient plasma was not available. Thus, on DEN-induced liver damage, EGFR in Kupffer cells/liver macrophages is required to induce expression of IL-6.
To further investigate whether IL-1 can induce IL-6 production in liver macrophages in an EGFR-dependent manner, we quantified IL-6 levels after incubation of isolated Kupffer cells/liver macrophages with IL-1β in vitro. IL-1β was able to induce IL-6 secretion in EGFRexpressing, but not in EGFR-deficient liver macrophages (Fig. 5d ). IL-6 production in Kupffer cells could be prevented by treatment with EGFR inhibitors in a dose-dependent manner ( Supplementary  Fig. 4a,b ). Inflammatory cytokines such as IL-17A, IL-22 and IL-23 were not detectable in the supernatants of EGFR f/f , EGFR ∆Mx or MYD88 −/− Kupffer cells following IL-1β or EGF stimulation ( Supplementary Fig. 4d ). IL-6 production was comparable between EGFR-expressing and deficient Kupffer cells after stimulation with toll-like receptor (TLR) agonists such as PolyIC, imiquimod and LPS ( Supplementary Fig. 4c) showing that EGFR-deficient Kupffer cells are not intrinsically impaired in IL-6 production. Thus, EGFRdeficient Kupffer cells cannot produce IL-6 in response to IL-1, indicating that EGFR-dependent IL-6 production is downstream of IL-1R signalling.
As IL-6 stimulates compensatory proliferation, we next analysed hepatocyte proliferation after DEN treatment in mice (Fig. 5e ). The strongest 5-bromodeoxyuridine (BrdU) incorporation was observed in EGFR ∆hep livers, probably because DEN-induced damage is high (because hepatocytes lack EGFR) and EGFR-expressing Kupffer cells/liver macrophages produce IL-6 to stimulate proliferation. In contrast, proliferation was lower in EGFR ∆Mx and control livers, probably because of impaired IL-6 production by EGFR-negative Kupffer cells/liver macrophages, and less severe DEN-induced damage in control (EGFR-expressing) hepatocytes (Fig. 5e ). Together, these results show that increased compensatory proliferation correlates with increased IL-6 levels and increased HCC formation.
Mechanism of IL-1β-induced IL-6 production by EGFR
To investigate the molecular mechanism by which EGFR signalling leads to IL-1-induced IL-6 production in Kupffer cells, we measured EGFR ligand expression following IL-1β stimulation and found that, except for betacellulin (BTC), all other EGFR ligands were significantly induced (Fig. 5f ). TACE (also known as ADAM17), a metalloprotease proteolytically releasing EGFR ligands 31 , was also induced by IL-1β ( Fig. 5f ). TACE and EGFR ligands were not expressed in MYD88 −/− Kupffer cells, indicating that their induction is under direct control of IL-1R signalling (Fig. 5f) . EGFR ligands and TACE were also induced by IL-1β in Kupffer cells lacking EGFR (EGFR ∆Mx ), suggesting EGFR-independent Supplementary Table 1 .
transcriptional regulation (Fig. 5f ). Consistent with this, the release of amphiregulin (AR) into the culture medium of IL-1β stimulated Kupffer cells was significantly increased in both EGFR-expressing and deficient Kupffer cells, but did not occur in MYD88 −/− Kupffer cells or when inhibiting TACE (TAPI-1) (Fig. 5g ). AR release could be blocked by inhibiting IKK (Sc-514), but not by inhibiting JNK (SP600125) or p38 (SB203580) signalling (Fig. 5g) , demonstrating that release of AR occurs through IKK-dependent activation of TACE.
These results demonstrate that IL-1R signalling in Kupffer cells controls expression of EGFR ligands and TACE, which probably leads to EGFR activation and downstream IL-6 production. To test this, we analysed IL-6 production in isolated Kupffer cells/liver macrophages in the presence of various inhibitors. TACE-1 and EGFR inhibitors blocked IL-1β-induced release of IL-6 in EGFR-expressing Kupffer cells to a similar extent as observed in MYD88 −/− and EGFR-deficient Kupffer cells (Fig. 5h ). This demonstrates a linear pathway from IL-1R signalling through MYD88, TACE and EGFR ligands to EGFR signalling and IL-6 production.
On the basis of these results, we hypothesized that direct stimulation of EGFR would induce IL-6 in Kupffer cells. Indeed EGF was equally potent to IL-1β in inducing IL-6 production in EGFR-expressing Kupffer cells (Fig. 5h,i) . Importantly, EGF, but not IL-1β, was able to fully restore IL-6 production in MYD88 −/− Kupffer cells (Fig. 5i) . These results indicate that EGFR activation and IL-6 production are downstream of IL-1R/MYD88 signalling. Consistent with this, IL-6 production by Kupffer cells/liver macrophages induced by either EGF or IL-1β was prevented in the absence of EGFR. Preincubation of EGFR-positive liver macrophages with JNK, p38 or IKK inhibitors also inhibited IL-6 production induced by either EGF or IL-1β, indicating the importance of JNK, p38 and NFκB signalling downstream of EGFR in mediating IL-6 production ( Fig. 5h,i) .
To demonstrate activation of EGFR, we analysed EGFR phosphorylation in isolated Kupffer cells. IL-1β stimulation was able to induce EGFR phosphorylation in EGFR-expressing Kupffer cells to a similar extent to EGF. This did not occur in EGFR-deficient (EGFR ∆Mx ) Kupffer cells ( Supplementary Fig. 4e,f) . IL-1β-induced EGFR transactivation was blocked by p38 inhibition but not by JNK or IKK inhibition, suggesting that activation of p38 is necessary for EGFR activation ( Supplementary Fig. 4e) . A similar requirement for p38 for EGFR transactivation by LPS has been recently described 32 . JNK, p38, IKKα/β and NFκB phosphorylation following IL-1β stimulation of EGFR-expressing and deficient Kupffer cells could be efficiently blocked by respective inhibitors (Supplementary Fig. 4e ). In addition to IKK and NFκB, JNK and p38 were also activated following EGF stimulation of EGFR f/f Kupffer cells ( Supplementary Fig. 4f ). Together, our data show that IL-1β stimulation of Kupffer cells leads to induction of EGFR ligands and ADAM17 with subsequent p38-dependent EGFR transactivation required for IL-6 production through JNK, p38 and IKK ( Supplementary Fig. 5 ).
DISCUSSION
EGFR is frequently overexpressed in human HCC, but its relevance for malignant progression is poorly understood. Our finding on the tumour-promoting role of EGFR in Kupffer cells might provide a possible explanation for the poor response of unstratified advanced stage HCC patients to EGFR targeted therapies. On the basis of our results, we would predict that only HCC patients with EGFR expression in liver macrophages will show a therapeutic effect with EGFR inhibitors (provided that liver macrophages are targeted by EGFR inhibitors). If EGFR is expressed only in tumour cells of HCC, we anticipate that EGFR inhibitors may even promote tumorigenesis, because our genetic results revealed that loss of EGFR in hepatocytes promotes HCC. Clinical follow-up studies are needed to re-evaluate the use of EGFR inhibitors in HCC, and to consider the possibility of targeting specific cell populations. At this stage, it is also possible that EGFR-expressing Kupffer cells play a tumour-promoting role only in the early stages of HCC development. Should this be true, patients with advanced stage HCC would probably not benefit from EGFRtargeted therapies. However, patients with HBV or HCV infections might benefit from EGFR inhibitor treatment in early disease stages to prevent HCC development. It will therefore be interesting to explore the predictive power of EGFR expression in Kupffer cells also in patients in more advanced disease stages. Treatment of patients with EGFR-positive Kupffer cells with EGFR inhibitors selectively targeting Kupffer cells could allow for improved HCC treatment in preselected patient populations.
Our results also highlight the complexity and provide mechanistic insights of EGFR signalling in hepatocarcinogenesis ( Supplementary  Fig. 5 ). We show that EGFR plays a hepatoprotective role during DEN-induced liver damage, as absence of EGFR renders hepatocytes more susceptible to DEN-induced damage, leading to increased IL-1β secretion and subsequent enhanced stimulation of Kupffer cells. This occurs in both mouse models lacking EGFR in parenchymal cells (EGFR ∆hep and EGFR ∆Mx mice). However, IL-6 production in Kupffer cells is strictly dependent on EGFR expression and occurs in a bimodal way involving first IL-1R/MYD88 signalling followed by TACE/EGFR-L production and p38-dependent EGFR transactivation. In mice lacking EGFR only in hepatocytes (EGFR ∆hep ), IL-6 secretion and compensatory proliferation are elevated, leading ultimately to increased HCC formation. Further deletion of EGFR from Kupffer cells/macrophages (EGFR ∆Mx and EGFR ∆hep/∆mac mice) impairs HCC development, despite increased liver damage, as EGFR-deficient Kupffer cells cannot produce IL-6 to stimulate compensatory proliferation ( Supplementary Fig. 5 ). In conclusion, we have discovered a crucial role for EGFR signalling in Kupffer cells/macrophages during inflammation-driven HCC formation, demonstrating that EGFR signalling plays a tumour-promoting function in non-tumour cells. Thus, EGFR-positive Kupffer cells might constitute a future prognostic marker and could potentially represent a target for HCC therapy.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary Information is available in the online version of the paper METHODS Mice and genotyping. EGFR f/f , EGFR ∆hep and EGFR ∆Mx mice have been previously described 25 . EGFR ∆mac and EGFR ∆hep/∆mac mice were generated by crossing EGFR f/f or EGFR ∆hep mice with LysM-Cre (ref. 33) transgenic mice. Male mice used in this study were kept in the facilities of the Medical University of Vienna in accordance with institutional policies and federal guidelines. Inducible EGFR deletion in EGFR ∆Mx mice was achieved by three consecutive intraperitoneal injections with pIpC (400 µg) every third day in adult mice or by three consecutive intraperitoneal injections with pIpC (150 µg) at days 9, 11 and 13 after birth. To genotype Cre transgenic mice a forward primer (Cre-F (5 -CAT ACC TGG AAA ATG CTT CTG TCC-3 ) and a reverse primer situated in the Cre transgene (Cre-R (5 -CCCAGAAATGCCAGATTACG-3 ) were combined. To genotype Alfp-Cre; LysM-Cre double transgenic mice, promoter-specific primers for the particular transgenes (Alb (5 -GCAAACATACGCAAGGGATT-3 ) or LysM (5 -GAGGGATGAAATTCCTGCAA-3 )) were combined with the Cre-R primer. The primers ∆-EGFR-F (5 -GCCTGTGTCCGGGTCTCGTCG-3 ) and ∆-EGFR-R (5 -CAACCAGTGCACCTAGCCTGGC-3 ) were used to detect deletion of EGFR (∆-EGFR). The mice were of mixed 129/Sv × C57BL/6 × CBA/J genetic background, and in all experiments EGFR-expressing littermates (EGFR f/f or Cre+ or EGFR +/+ ) served as controls to the respective EGFR deleted mice. For tumour experiments, age of mice is indicated in the relevant results section and the figure legends. For all short-term experiments, mice were between 8 and 12 weeks of age.
Liver tumour induction in mice by DEN/PB. Liver tumours were induced
by chemical carcinogenesis in male mice according to the scheme shown in Supplementary Fig. 1a . Mice were sacrificed when liver tumours were visible in EGFR f/f , EGFR f /+ or EGFR +/+ Cre+ littermate control mice, which occurred around 36 weeks in the Alfp-Cre, around 46 weeks in the Mx-Cre and around 63 weeks in the Alfp-Cre; LysM-Cre double transgenic background. The genetic background of the mice was mixed (C57BL/6 × 129/Sv × CBA/J), but varied between the different Cre lines, thus explaining the difference in the timing of tumour development. For each experiment, we show EGFR f/f littermates as controls. To exclude Cre-mediated effects, we confirmed that EGFR f /+ or EGFR +/+ Alfp-Cre, Mx-Cre, LysM-Cre mice developed the same defects as EGFR f/f controls. Liver injury after DEN injection (100 mg kg −1 body weight) was determined by measuring circulating aspartate transaminase/alanine transaminase (Reflotron, Roche) and by quantifying necrotic areas using H&E stained sections at the times indicated.
Histology. Liver tissue was fixed in 4% paraformaldehyde for 24 h, dehydrated, embedded in paraffin and sectioned (5 µm). Sections were stained with H&E (Sigma) for quantification of necrosis after DEN-induced damage and for quantification of liver tumours. Images were obtained with a Nikon eclipse 80i microscope and quantification was done by Adobe Photoshop CS4 (Adobe). Quantification of liver tumours was carried out on two H&E sections per liver, which were at least 200 µm apart, as previously described 25 .
Immunohistochemistry and immunofluorescence. Protocols for Ki67 staining, BrdU in situ detection, TUNEL and immunoblotting have been previously described [34] [35] [36] [37] . In brief, for antigen retrieval, paraffin-embedded tissue was treated with Target Retrieval Solution (Dako) unless otherwise stated in the manufacturer's instructions, and further processed for immunohistochemistry according to the manufacturer's recommendation. To analyse cell proliferation, mice were injected intraperitoneally with 100 µg g −1 body weight of BrdU. Stainings for BrdU (Caltag) and Ki67 were carried out using an ABC staining kit (Vector Laboratories). An in situ cell-death detection kit (Roche) was used for TUNEL staining. The number of positive cells was determined by manual counting of the indicated number of high-power fields. For immunofluorescent staining, livers were embedded in optimal cutting temperature compound (Sakura) for frozen section preparation (4 µm) and fixed according to the manufacturers' suggestions for each respective antibody. For immunohistochemistry and immunofluorescent stainings, antibodies against the following antigens were used: EGFR (CST no. 4267, clone D38B1, 1/50), F4/80 (Serotec MCA497R, clone CI:A3-1, 1/100, and eBioscience 14-4801, clone BM8, 1/100), Ki67 (Novocastra NCL-Ki67p, 1/1000), CD68 (abcam ab955, clone KP1, 1/200), HMGB1 (CST no. 3935, 1/100) and active caspase 3 (R&D Systems AF835, 1/2000). Secondary antibodies were purchased from Molecular Probes and Vector Laboratories. Confocal microscopy images were taken with a Zeiss-LSM 700 microscope and evaluated using the ZEN2010 software. For mean fluorescence intensity measurements, confocal microscopy images were analysed with ImageJ. Single F4/80-positive cells were selected using the ellipsoid selection tool and analysed for mean fluorescence intensity of EGFR expression (Alexa 488) by using the Histogram tool (only the value of the green channel was used).
Western blot analysis. Protein lysates were prepared according to standard protocols. Lysed protein was resuspended in denaturing protein-loading buffer.
Proteins were separated by SDS-PAGE and transferred to polyvinylidene difluoride membranes (Millipore). The following antibodies were used: pEGFR (Tyr1068  CST no Hepatocyte and Kupffer cell culture. Hepatocytes and Kupffer cells were isolated after liver perfusion according to previously published protocols 25 . In brief, livers were perfused at 7 ml min −1 through the portal vein with perfusion buffer containing collagenase (Gibco). The resulting cell suspension was passed through a 70 µm cell strainer (BD Falcon Biosciences). Cell fractions were separated by Percoll gradients. Cells were either directly used for further analysis or cultured as follows. Hepatocytes were plated onto collagen pre-coated cell culture dishes and cultured in HepatoZYME-SFM (Gibco) supplemented with 10% FCS, 2 mM glutamine and 1% penicillin-streptomycin. Hepatocytes were treated either with the indicated amounts of DEN for 24 h or with 10 ng ml −1 TNFα (eBioscience) in the presence of cycloheximide (100 µg ml −1 , Sigma) for 12 h. Kupffer cells were plated onto uncoated cell culture dishes (50,000 per well for 96-well plates) in RPMI 1640 supplemented with 10% FCS, 2 mM glutamine and 1% penicillin-streptomycin for 24 h followed by overnight starvation (in 0.5% FCS containing medium for cytokine induction, serum-free medium for signalling experiments). Kupffer cells were stimulated with IL-1β (10 ng ml −1 , eBioscience), EGF (10 ng ml −1 , Lonza), polyIC (20 µg ml −1 , GE Healthcare), imiquimod (12 µg ml −1 , Invivogen) and LPS (10 ng ml −1 , Invivogen) for the time period indicated. Whenever indicated, Kupffer cells were preincubated for 5 h (for cytokine secretion) or 1 h (for signalling experiments) before stimulation with the following inhibitors: BIBW2992 (0.005-20 µM, Selleck), cetuximab (0.01-1 µg ml −1 , Merck), TAPI-1 (10 µM, Peptides International), SP600125 (25 µM, Calbiochem), SB203580 (10 µM, Cell Signaling), and SC-514 (100 µM, Calbiochem). As the number of Kupffer cells that can be recovered from one mouse is very low, it was technically impossible to carry out western blot analysis for all indicated signalling molecules on one single batch of Kupffer cells. Usually Kupffer cells from two livers of the same genotype were pooled together to obtain around 20-30 µg of protein lysate, which was sufficient for one western blot.
Patient material and immunohistochemistry. Human samples were collected following informed consent according to the established protocol approved by the Ethics Committee of the Eastern Hepatobiliary Surgery Hospital and the Medical University of Vienna. The 129 HCC patients of the Chinese cohort were randomly taken from the pool of HCC patients undergoing curative resection in the Eastern Hepatobiliary Surgery Hospital between January 2002 and June 2006. None of these HCC patients received preoperative anticancer treatment. The normal liver tissues were collected from the distal normal liver sections of patients undergoing surgery for liver haemangioma, who did not show any evidence of chronic liver disease.
The 108 HCC patients of the European cohort were randomly taken from a pool of patients who underwent orthotopic liver transplantation for HCC at the Medical University of Vienna as previously published 38, 39 . None of these HCC patients received preoperative anticancer treatment. Immunohistochemistry and quantitative analyses (scoring) on all human tissues (Chinese and European cohorts) were carried out by the same laboratory (China) in a blinded manner following standard procedures.
The slides were incubated with the following primary antibodies: anti-EGFR (CST no. 4267, clone D38B1, 1/50); anti-CD68 (macrophage marker, abcam ab955, clone KP1, 1/200). Staining for EGFR in hepatocytes or Kupffer cells for both the European and Chinese patient cohorts was semi-quantitatively examined and blindly scored by two independent observers using the following scale: 0, negative staining (0-10% positive); +, weak signal (10-20% positive); ++, intermediate signal (20-50% positive); +++, strong signal (>50% positive), as previously described 40 . There were only slight variations between the scoring results of the two pathologists, and in such cases the lower scoring was taken to generate Table 1 .
Statistical analysis.
Mouse experiments. The mouse experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Sample size calculation. For tumour studies we considered 10 mice per group to detect a relevant difference in means of 1.5 withingroup s.d. at a two-sided significance level of 0.05 and a power of 90%, which ensures 80% power in case of a 20% drop-out rate. For the EGFR ∆hep/∆mac experiment six mice per group were considered, which ensures a 90% power to detect a difference in means of two s.d. at the same significance level of 0.05. Experiments in mice (various injections, ex vivo cell and tissue isolations and so on) were carried out as indicated in the figure legends. Quantifications on histological samples were carried out by counting/measuring microscopic fields (HPF where indicated) as indicated in the legends. Data are presented as mean ± s.d. or mean ± s.e.m. Student's t-test for independent samples and unequal variances was used to assess statistical significance ( * P < 0.05, * * P < 0.01, * * * P < 0.001). Each tumour measurement contributed by one animal is the mean value over several liver sections. On the basis of the central limit theorem, we can assume a normal distribution of these animal-specific means even if the underlying variable is not perfectly normally distributed. All statistical analyses were carried out with the SPSS18.0 software. A two-sided p < 0.05 was considered statistically significant.
Human material. The statistical analyses were carried out by the respective Chinese and Viennese laboratories. The experiments were not randomized. Staining for EGFR in hepatocytes or Kupffer cells of human patient material for both the European and the Chinese patient cohorts was semi-quantitatively examined and blindly scored by two independent observers. OS in both patient cohorts was defined as the time between the dates of surgery and death or the last follow-up. DFS was defined as the time between the dates of surgery and recurrence. If recurrence was not diagnosed, patients were classified on the date of death or the last follow-up. Survival curves were calculated using the Kaplan-Meier method. Median survival times (OS) and their 95% confidence intervals were reported. The survival in the European cohort is low for a current transplant population because many patients were transplanted with tumours that were too large (outside the now accepted Milan criteria) as previously described 30 . The log-rank test was used to assess the effects of patient variables on DFS and OS. Supplementary Table 1 . 
